Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation
Top Cited Papers
- 8 May 2012
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 60 (8), 738-746
- https://doi.org/10.1016/j.jacc.2012.03.019
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCirculation, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeThe New England Journal of Medicine, 2012
- A New Landscape for Stroke Prevention in Atrial FibrillationStroke, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research DatabaseBMJ Open, 2011
- Newly Identified Events in the RE-LY TrialThe New England Journal of Medicine, 2010
- Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilateThrombosis and Haemostasis, 2010
- Indirect comparisons of treatments based on systematic reviews of randomised controlled trialsInternational Journal of Clinical Practice, 2009
- Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviewsBMJ, 2009
- Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm AssociationEP Europace, 2007